Radioiodine-131 Therapy for Well-Differentiated Thyroid Cancer--A Quantitative Radiation Dosimetric Approach: Outcome and Validation in 85 Patients

• Published in: The Journal of nuclear medicine (1978) Vol. 33; no. 6; pp. 1132 - 1136
• Main Authors: Maxon, Harry R., III, Englaro, Emanuela E, Thomas, Stephen R, Hertzberg, Vicki S, Hinnefeld, Jerry D, Chen, L.S, Smith, H, Cummings, Dwight, Aden, Michael D
• Format: Journal Article
• Language: English
• Published: United States Soc Nuclear Med 01.06.1992
• Subjects: Adenocarcinoma - epidemiology; Adenocarcinoma - radiotherapy; Adenocarcinoma - surgery; Carcinoma, Papillary - epidemiology; Carcinoma, Papillary - radiotherapy; Carcinoma, Papillary - surgery; Combined Modality Therapy; Evaluation Studies as Topic; Humans; Iodine Radioisotopes - therapeutic use; Prospective Studies; Radiotherapy Dosage; Thyroid Neoplasms - epidemiology; Thyroid Neoplasms - radiotherapy; Thyroid Neoplasms - surgery; Thyroidectomy
• ISSN: 0161-5505; 1535-5667

For almost five decades, 131I treatment of thyroid cancer has been based empirically on administered activity rather than on actual radiation doses delivered. In 1983, we defined radiation dose thresholds for successful treatment. This report is concerned with the subsequent validation of those thresholds in 85 patients. The successful ablation of thyroid remnants occurred after a single initial 131I administration in 84% of inpatients and in 79% of outpatients when treatment was standardized to a radiation dose of at least 30,000 cGy (rad). Administered activities low enough to permit outpatient therapy could be used in 47% of the patients. Lymph node metastases were treated successfully in 74% of patients with a single administration of 131I calculated to deliver at least 8,500 cGy (rad). For athyrotic patients with nodal metastases only, success was achieved in 86% of patients at tumor doses of at least 14,000 cGy (rad). These success rates are equal to or better than those reported with empiric methods of 131I administration. The individualized treatment planning selectively allocates hospitalization and higher exposures to 131I to those patients who require them.